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Abstract In the present study we investigated the feasi-
bility and effectiveness of a new biweekly schedule of
fotemustine (FTM) in patients with recurrent glioblastoma,
after at least one previous treatment. The primary endpoint
was progression-free survival at 6 months; secondary
objectives were clinical response, overall survival, disease-
free survival, and toxicity. Forty patients (median age
52.8 years; median Karnofsky Performance Status at pro-
gression 90) underwent second-line chemotherapy with
FTM. Selected patients were previously treated with a
standard radiotherapy course with concomitant temozolo-
mide (TMZ). After tumor relapse or progression proven by
magnetic resonance imaging (MRI), all patients underwent
chemotherapy with FTM, given intravenously at dose of
80 mg/m
2 every 2 weeks for ﬁve consecutive administra-
tions (induction phase), and then every 3 weeks at 100 mg/
m
2 as maintenance. A total of 329 infusions were adminis-
tered; the median number of cycles administered was 8. All
patients completed the induction phase, and 29 patients
received at least one maintenance infusion. Response to
treatment was assessed using MacDonald criteria. One
complete response [2.5%, 95% conﬁdence interval (CI):
0–10%], 9 partial responses (22.5%, 95% CI: 15–37%), and
16 stable diseases (40%, 95% CI: 32–51%) were observed.
Median time to progression was 6.7 months (95% CI:
3.9–9.1 months). Progression-free survival at 6 months was
61%. Median survival from beginning of FTM chemother-
apy was 11.1 months. The schedule was generally well tol-
erated; the main toxicities were hematologic (grade 3
thrombocytopenia in two cases). To the best of our knowl-
edge,thisistheﬁrstreportspeciﬁcallydealingwiththeuseof
a biweekly induction schedule of FTM. The study demon-
strates that FTM has therapeutic efﬁcacy as single-drug
second-line chemotherapy with a favorable safety proﬁle.
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Introduction
Glioblastoma [glioblastoma multiforme (GBM)] is the
most common type of adult primary central nervous system
tumor. Median survival of patients with conservatively
treated GBM is 14 weeks; by surgical resection alone,
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addition of chemotherapy, 40–50 weeks [1]. The gold-
standard ﬁrst-line treatment for GBM is based on a com-
bination of radiotherapy and temozolomide (TMZ), as
derived from the study by Stupp et al. [2]. In that study,
patients were randomized to radiotherapy alone or radio-
therapy plus TMZ. The hazard ratio (HR) for death among
patients treated with radiotherapy plus TMZ, when com-
pared with those who received radiotherapy alone, was
0.63 (95% conﬁdence interval, 0.52–0.75; P = 0.001), thus
indicating use of this combination for treatment of GBM
[2]. The 5-year survey of that study conﬁrmed an advan-
tage for combined therapy, with overall survival (OS) at
5 years of 9.8% (6.4–14.0%) with TMZ versus 1.9%
(0.6–4.4%) with radiotherapy alone (HR 0.6, 95% CI:
0.5–0.7; P = 0.0001) [3]. Despite the aggressive ﬁrst-line
therapy, and the recent results with surgery, radiation
therapy, and adjuvant chemotherapy, tumors invariably
recur and median survival is 15 months [2]; the most
favorable patient group with methylated O6-methylgua-
nine-DNA methyltransferase (MGMT) promoter treated
with this combination had median survival of 22 months
[4].
The problem of unsatisfactory local control of recur-
rence continues to exist even after application of relatively
high-dose radiotherapy; in fact, tumor progression usually
starts again after 20–27 weeks. There are no clearly
established chemotherapy regimens for treatment of
recurrent GBM. TMZ is the best documented agent and has
shown a single-agent response rate of 5–8% in GBM, and
of 35% in anaplastic astrocytoma [5]. Trials in recurrent
GBM have used platinum, procarbazine (PCB), enzastaurin
(alone or in combination with carboplatin), and different
combinations of these drugs. The response rates reported
are up to 20–30%, with short progression-free intervals and
median survival rarely exceeding 6 months. In general,
studies about pharmacological treatment of recurrent GBM
have given controversial results [6]. Recent phase II trials
have demonstrated activity of nitrosoureas such as fote-
mustine (FTM) in recurrent GBM [7–10]. FTM is a
third-generation nitrosourea with an alkylating cytotoxic
activity, characterized by a phosphoalanine carrier group
grafted onto the nitrosourea radical, which gives it high
lipophilicity that allows it to cross the blood–brain barrier
[11, 12]. The drug, developed some 20 years ago, has been
employed in treatment of metastatic melanoma, hemato-
logical malignancies, and on the basis of its pharmacoki-
netic properties, in brain tumors, either primitive or
metastatic [7]. FTM showed both in vitro and in vivo
marked antineoplastic activity on human GBM and
medulloblastoma cell lines [8, 9]. In a phase I study,
Khayat et al. [13] detected the dose of FTM to be used in
clinical practice: 100 mg m
2 in i.v. infusion of 1 h,
administered on days 1, 8, and 15 (induction), to be repe-
ated after 4–5 weeks every 21 days (maintenance). In
another two phase II trials, FTM activity was conﬁrmed to
be 15.5–26% in recurrent GBM [10, 14] if administered
with similar schedules. Myelosuppression represented the
most relevant side-effect, being reported also in more than
30% of the subpopulation pretreated with chemotherapy. In
the last months, several phase II studies have evaluated
both efﬁcacy and safety of FTM as second-line chemo-
therapy in patients previously treated with TMZ plus
radiotherapy as adjuvant treatment in 160 patients with
recurrent GBM. The treatment was active, with a promis-
ing disease control rate (DCR) and a favorable safety
proﬁle. These data are interesting if we consider that most
of the patients had poor performance status with compro-
mised hematological status [7]. In the trial by Brandes
et al. patients with progressive GBM after radiotherapy
plus concomitant and/or adjuvant TMZ received 3-weekly
doses (100–75 mg/m
2) of FTM followed, after 5 weeks
rest, by FTM (100 mg/m
2) every 3 weeks. Forty-three
patients were enrolled. Progression-free survival at
6 months was 20.9%; 3 patients (7.1%) had partial
response (PR), and 15 (34.9%) had disease stabilization
(SD). Median survival was 6 months (95% CI:
5–7 months) [15]. It is noteworthy that, after the inclusion
of the ﬁrst three patients, the protocol was amended to
reduce FTM dosage during induction therapy to 75 mg/m
2
due to occurrence of grade 4 thrombocytopenia. In another
study, on 40 patients with recurrent pretreated GBM, the
authors conﬁrmed that low-dose FTM at 65–75 mg/m
2
(induction phase) had activity comparable to that of the
conventional schedule [16]. In another two phase II stud-
ies, FTM, at a similar induction schedule, was used for
treatment of recurrent GBM after previous combination
therapy with radiotherapy and TMZ [17, 18] with favorable
results in terms of both response rate and progression-free
survival at 6 months (PFS-6). Global incidence of acute
toxicity effects was 40% (all grades) during treatment with
FTM. Preclinical evidence suggests that the MGMT repair
protein is involved in resistance to alkylating agents
including FTM [19]. However, there is little information
available regarding the clinical correlation between MGMT
promoter methylation status and the anticancer activity of
FTM.
On the bases of all the previous considerations, we
performed a phase II trial enrolling 40 patients with
relapsing GBM, pretreated with radiotherapy plus TMZ, in
order to assess both efﬁcacy and the safety proﬁle of a new
schedule of FTM administrated at low chronic doses fol-
lowed by a maintenance phase. The objectives of the trial
are evaluation of: PFS-6, response rate, toxicity, and any
correlation of the latter with MGMT gene promoter meth-
ylation status.
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Patient eligibility criteria
Adult patients with recurrent or progressive, histologically
conﬁrmed GBM following surgery, and radiotherapy and
chemotherapy with TMZ, for at least three cycles accord-
ing to Stupp protocol, were enrolled in the trial. Progres-
sion was documented by MRI or computed tomography
(CT) scans at least 3 months after the end of radiotherapy
or evidence of progressive disease (PD) on two consecutive
radiologic investigations. Patients were required to have
proven evidence of tumor recurrence or progression and
Karnofsky Performance Status [70 at the moment of
starting FTM chemotherapy. Patients needed to have:
minimum life expectancy of 3 months; measurable disease
with contrast enhancement using MRI and/or CT scans,
assessed within 2 weeks before study entry; and at least
one unidimensionally measurable lesion of 2 cm in diam-
eter by MRI. Other eligibility criteria included adequate
hematologic function with white cell count [2 9 10
9/l,
platelets count [100,000/mm
2, and hemoglobin [8 g/dl,
renal function with creatinine level\2 mg/dl, and adequate
liver function with aspartate aminotransferase level\1.59
the upper limit of normal. The Institutional Ethical Com-
mittee approved the protocol, and patients were required to
provide informed consent before beginning the treatment.
Treatment plan
Patients were treated with 1 h intravenous infusion of FTM
according to the following schedule: induction phase with
80 mg/m
2 FTM on days 1, 15, 30, 45, and 60 followed by a
4-week rest period. After this period, in nonprogressive
patients, maintenance therapy was given with 80 mg/m
2
FTM every 4 weeks until progression or unacceptable
toxicity. In the case of toxicity occurrence, if treatment
suspension was prolonged by more than 2 weeks beyond
the next scheduled cycle of the planned treatment, the
patient was permanently withdrawn from the study.
Response and toxicity assessment
Tumor evaluation was performed through brain MRI and
clinical examination. Response to treatment was assessed
at baseline, after the induction phase, before the mainte-
nance schedule, and every three cycles thereafter, or
whenever disease progression was clinically suspected.
MacDonald et al. [20] criteria were uniformly adopted for
response evaluation. According to MacDonald, the fol-
lowing four response categories can be identiﬁed: (1)
complete response (CR): disappearance of all enhancing
tumor on consecutive CT or MRI scans at least 1 month
apart, off steroids, and neurologically stable or improved;
(2) PR: -50% reduction in size of enhancing tumor on
consecutive CT or MRI scans at least 1 month apart, ste-
roids stable or reduced, and neurologically stable or
improved; (3) progressive disease (PD):[25% increase in
size of enhancing tumor or any new tumor on CT or MRI
scans, or neurologically worse, and steroids stable or
increased; (4) stable disease (SD): all other situations.
Neurological status was assessed by considering signs and
symptoms possibly correlated with progression, as com-
pared with the previous examination; each variation in
daily corticosteroids dosage was recorded. Toxicity was
evaluated according to the National Cancer Institute (NCI)
common toxicity criteria (CTC, version 3.0) during routine
controls at 2-weekly intervals or, if clinically indicated, at
weekly intervals. Monitoring of serum chemistry and blood
cell counts was performed prior to each cycle of therapy at
2-weekly intervals during induction, and at 4-weekly
intervals during maintenance. In case of hematological
toxicity necessitating delay of chemotherapy administra-
tion, blood counts were performed at weekly intervals.
Study objectives and statistical analysis
The study is an open, multicenter, nonrandomized, single-
arm, phase II study in recurrent GBM patients. The pri-
mary efﬁcacy endpoint of the study was the percentage of
patients free from disease, PFS-6. PFS was measured from
initiation of FTM to progression or death due to any cause
or last follow-up assessment, whichever came ﬁrst. OS was
measured from start of FTM to death for any reason, or last
follow-up assessment. Secondary endpoints were the
following: rate of best observed response, duration of
objective response and stabilization, duration of CR, time
to disease progression, OS, and toxicity. Other objectives
were assessment of functional status, of the amount of
symptomatic drug assumption, and evaluation of MGMT
methylation and its correlation with clinical outcome. Drug
activity was evaluated based on a one-stage Fleming [21]
study design for determination of response rates based on a
single treatment group. Median time to progression and
median time to survival were also estimated with their 95%
conﬁdence interval; PFS-6 and OS were calculated using
the Kaplan–Meier method [22] (Fig. 1). MGMT promoter
methylation analysis was performed on tissues taken from
the primary surgical specimen before treatment with
radiotherapy and TMZ. Genomic DNA was isolated from
one parafﬁn section of malignant glioma tissue; it was
subjected to bisulﬁte treatment, and modiﬁed DNA was
analyzed by methylation-speciﬁc protein C reactive (PCR)
performed in a two-step approach.
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Patient characteristics
Between October 2006 and December 2008, 40 patients
were enrolled. Main patient and tumor characteristics are
summarized in Tables 1, 2, and 3. Median age was
52.8 years (range 31–75 years) and median KPS was 90.
All 40 patients had histologically proven recurrent GBM.
Twenty-three patients underwent surgery with macro-
scopically radical resection. Each patient had completed
external-beam radiation therapy (60 Gy/30 fractions) con-
currently and/or followed by adjuvant TMZ. Median
number of TMZ cycles was 6 (range 3–24). No patient
underwent a second surgical procedure at the time of
progression following TMZ administration. Median time
interval between surgery and recurrence was 9.5 months
(range 3.3–34.2 months); median time interval between
diagnosis and FTM induction was 11.6 months (range
5.7–42 months).
Clinical activity evaluation
All patients included in the study were assessable for
response. Median follow-up time was 18 months. Among
the 40 assessable patients, 1 had CR (2.5%, 95% CI:
0–10%) and 9 had PR (22.5%, 95% CI: 15–37%). SD was
noted in 16 patients (40%, 95% CI: 32–51%), and median
duration of SD in these 16 patients was 4.9 months (95%
CI: 1.9–9.1 months). On the other hand, median PFS of
responders was 9.0 months (95% CI: 7.98–10.02 months).
However, clinical beneﬁt (CR ? PR ? SD lasting
12 weeks) accounted for 65% (95% CI: 59.7–81.9%),
while 14 patients (35%) experienced disease progression.
All responses were conﬁrmed by independent centralized
review, and stable or decreased steroid dosage was con-
ﬁrmed in all patients at the time of recording response.
In the present trial we enrolled 14 patients with PD
recorded after or during TMZ adjuvant treatment. In detail,
six patients were in progression while receiving adjuvant
TMZ before completion of six cycles of therapy, and the
Fig. 1 Kaplan–Meier estimates of progression-free (a) and overall (b) survival time from study entry for the patients enrolled in the study
Table 1 Demographic characteristics of patients enrolled in the trial
n (%)
Sex
Female 11 (27.5)
Male 29 (72.5)
Age (years)
Median 52.8
Range 30–75
KPS
Median 90
Range 70–100
Radicality of surgical resection
Macroscopically radical 23 (57.5)
Partial 10 (25)
Biopsy 7 (17.5)
Initial grade
Glioblastoma 40 (100)
Radiotherapy ? TMZ
60 Gy RT ? TMZ 40 (100)
Interval between completion of TMZ and FTM initiation
Within 3 months 14 (35)
Beyond 3 months 26 (65)
MGMT status
Methylated 7 (17.5)
Unmethylated 17 (42.5)
Unknown 16 (40)
420 J Neurooncol (2011) 102:417–424
123eight remaining patients progressed after completion of
adjuvant TMZ and a treatment-free interval smaller than
3 months. We did not observe any clinical response in
these 14 patients, and only 4 of them achieved SD. Among
the 24 patients with data available regarding MGMT pro-
moter methylation status, DCR was greater in methylated
(3/7, 42%) than in unmethylated (6/17, 35%) MGMT
patients, but the difference was not statistically signiﬁcant
(P = 0.24). On the other hand, DCR was signiﬁcantly
greater in patients who started FTM at least 3 months after
TMZ administration had been concluded (16% versus 9%,
P = 0.004). Median PFS was 6.7 months (95% CI:
3.9–9.1 months). Median PFS-6 was 39%. Median OS
from beginning FTM chemotherapy was 11.1 months. No
signiﬁcant differences were found between median PFS,
evaluated using log-rank test, in relation to KPS (P = 0.42,
using cutoff value of KPS C80), age (P = 0.62, using
cutoff value of C65 years) or methylated or unmethylated
status of MGMT promoter (P = 0.18). Efﬁcacy of this
treatment was conﬁrmed by the decreased requirement for
medication to palliate neurologic symptoms. At baseline,
37 (92.5%) patients required corticosteroids, and 13
(32.5%) opioids. After 2 months of FTM treatment, these
percentages progressively decreased. In fact, at 2 months,
23 (57.5%) patients required corticosteroids, and 6 (15%)
opioids. These data conﬁrm the clinical beneﬁt of the
schedule used in the current study in this subset of patients.
Toxicity evaluation
Overall, 40 patients received a total of 329 infusions; the
median number of cycles administered was 8. All 40
patients completed the induction phase as planned. During
the induction phase the major toxicity was thrombocyto-
penia, which developed in 11 (27.5%) patients, 2 (5%) of
them with NCI-CTC grade 3 intensity, and neutropenia,
which developed in 9 (22.5%) patients, but only one (2.5%)
with grade 3 intensity. In our series we did not observe any
cases of lymphopenia. The most commonly reported
grade 3 nonhematological toxicities were nausea and
vomiting, in six (12.5%) and ﬁve (10%) patients, respec-
tively, without any grade 3 toxicity. Twenty-nine (72.5%)
patients started maintenance chemotherapy and received a
median of 4 cycles (range 2–12). During this period we
observed an increase of incidence of hepatic toxicity, with
a rise in ALT and AST values in ten patients (34%), three
of whom (10%) had NCI CTC grade 3 toxicity. Grade 2
and 3 thrombocytopenia was documented in seven (24%)
and two (7%) patients, respectively. Overall, the toxicity
incidence rate of FTM increased with the number of
completed cycles. FTM was generally well tolerated, and
treatment interruption due to toxicity was not observed in
our series; three patients had a delay of infusion of 1 week
because of hepatic toxicity, and another two patients
required dose reduction of 25% during maintenance.
Table 2 Clinical activity of the
schedule
Overall
response
No. of patients
(%)
CR 1 (2.5)
PR 9 (22.5)
Overall
response rate
10 (25)
No change 16 (40)
DCR 26 (65)
PD 14 (35)
Total 40 (100)
Table 3 Incidence of drug-related adverse events (safety popula-
tion), by grade of severity, during induction and maintenance
Adverse event Induction (n = 40) Maintenance (n = 29)
Leukopenia
Grade 1–2 7 (17.5) 4 (14)
Grade 3 1 (2.5) 1 (3.5)
Grade 4 – –
Neutropenia
Grade 1–2 8 (20) 4 (14)
Grade 3 1 (2.5) 2 (7)
Grade 4 – –
Thrombocytopenia
Grade 1–2 9 (22.5) 7 (24)
Grade 3 2 (5) 2 (7)
Grade 4 – –
Anemia
Grade 1–2 6 (15) 2 (7)
Grade 3 1 (2.5) –
Grade 4 – –
Nausea
Grade 1–2 5 (12.5) 3 (10)
Grade 3 – –
Grade 4 – –
Vomiting
Grade 1–2 4 (10) 3 (10)
Grade 3 – –
Grade 4 – –
Cutaneous rush
Grade 1–2 2 (5) –
Grade 3 – –
Grade 4 – –
Metabolic/laboratory AST/ALT
Grade 1–2 3 (7.5) 7 (24)
Grade 3 – 3 (10)
Grade 4 – –
AST aspartate transaminase, ALT alanine transaminase
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For most patients with newly diagnosed GBM, postopera-
tive radiotherapy plus TMZ has become the standard of
care [2]. Assuming that TMZ is moving rapidly into the
ﬁrst-line setting, the question arises whether it should be
given again in relapsed patients.
The choice of chemotherapy depended on whether the
patient had previously received chemotherapy as ﬁrst-line
therapy. Frequently, treatment decisions have to be made
based on case-by-case evaluation, depending on prior ther-
apy, time to relapse, tumor grade, and performance status
[23].Severalphase IIstudieshaveshownthatchemotherapy
approachescanprovidesomeencouragingresultsintermsof
efﬁcacy. Nitrosoureas, PCB, paclitaxel, TMZ, and cisplatin
were tested, although the impact on OS was minimal [24–
26]. In a large randomized, multicentre, open-label phase II
study that compared TMZ and PCB in 225 patients with
GBM at ﬁrst relapse, Yung et al. [27] demonstrated that the
6-month PFS rate for patients who received TMZ was 21%,
withanimprovementinpatienthealth-relatedqualityoflife.
Antiangiogenictherapyhasbeendemonstratedtorepresenta
promising novel approach for treatment of malignant brain
tumors. Recent clinical trials targeting vascular endothelial
growth factor (VEGF) signaling with bevacizumab plus iri-
notecan have shown promising radiographic and clinical
responses,whilealsoconﬁrmingadequatesafetyinrecurrent
GBMpatients[28].Wehavealsotoconsiderthehighimpact
on national health systems of the pharmaco-economic
aspects of this regimen, as both irinotecan and bevacizumab
are extremely expensive agents.
FTM represents an evolution of nitrosourea that was
synthesized to facilitate passage through the blood–brain
barrier by the addition of a phosphoalanine vector. The use
and efﬁcacy of this drug, using the conventional schedule
[14] in patients with recurrent GBM, are known but limited
by considerable toxicity. Hematological toxicity is
observed in nearly 40% of patients receiving FTM, and
thrombocytopenia and leukopenia are more frequent and
signiﬁcant in pretreated patients.
Myelosuppression was the most common adverse event
that occurred, mainly during the induction phase of treat-
ment. We cannot ignore that the traditional schedule of
FTM including the induction phase achieved hopeful
clinical results. On the basis of these considerations, we
planned a new treatment that maintains the global dosage/
time ratio but with different fractionation, similarly to our
experience reported for low protracted dose of TMZ [29].
In fact, metronomic administration of cytotoxic drugs is
proven to be less toxic than acute administration, causing
alsoimportantanddifferentbiologicaleffectsontumorcells.
In the traditional schedule, patients received 400 mg/m
2
FTM during an 8-week period (days 1, 8, and 15 every
28–35 days), with considerable toxicity that frequently
does not allow completion of the schedule. In the present
trial, the patients received, during the same period,
400 mg/m
2 FTM fractionated to days 1, 15, 30, 45, and 60,
and we did not observe any serious adverse events that
compromised the dose density of this treatment. In our
opinion, this could be the explanation for the promising
results obtained in our series. The results of the present
study show that fractionated FTM monotherapy is able to
achieve response in 25% of patients, with an overall DCR
of 65%. These results are remarkable, since they were
observed in a pretreated population that had received one
previous line of chemotherapy. However, our favorable
data also have to be interpreted on the basis of ‘‘pseudo-
progression’’ occurrence that could overestimate the results
obtained in the present trial. We tried to reduce the inﬂu-
ence of the occurrence of such a pseudoprogression effect
by excluding patients who experienced progression within
3 months from radiation therapy according to NCI of
Canada recommendations [30]. Moreover, none of the 14
patients enrolled in the study and who ended adjuvant TMZ
treatment in the 3 months achieved an objective response
during or after FTM therapy. However, we cannot exclude
that some of the recorded responses could be resolution of
radionecrosis, since we do not have data from amino-acid
positron emission tomography (PET) and/or MRI spec-
troscopy demonstrating the speciﬁc features of tumor tis-
sue. In addition, pretreatment with an alkylating agent
could positively select for patients who will respond to
alkylating therapy in relapse. The results regarding the
activity of our schedule are in line with those reported in
the literature with single-agent FTM at the conventional
schedule of 100 mg/m
2 [10, 14]. However, these previous
experiences were characterized by important hematological
toxicity, as recently conﬁrmed by Brandes et al. [15]. In the
present study, we conﬁrmed these results in a larger pop-
ulation of patients, with a better DCR and toxicity proﬁle.
Our efﬁcacy data (PFS-6) are similar to those reported in
two other trials, by Scoccianti et al. [18] and Fabrini et al.
[17], but with a lower rate of grade 3–4 hematological
toxicities, likely due to the longer period of rest between
each induction phase. This is reasonable if we consider that
we use a similar intensive dose for induction phase, and
probably it may represent an explanation for the better
results than those obtained by Brandes et al. [15], even if
comparison across trials is always challenging. The crucial
role of the induction phase for the efﬁcacy of this drug was
recently shown in two studies exploring FTM in combi-
nation with either dacarbazine or PCB [31, 32]. In these
two trials the lower observed efﬁcacy, considered as
response rate (3–11%), is probably due to the different
schedule that, in our case, includes the weekly induction
phase. Our data conﬁrmed the absence of cross-resistance
422 J Neurooncol (2011) 102:417–424
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in TMZ-pretreated patients. PFS-6, the primary endpoint of
the protocol, was 61% and represents an encouraging result
compared with other experience with this drug or with
other chemotherapeutic or targeted agents [33] or using the
combination of irinotecan and bevacizumab. The treatment
was well tolerated, underlining the lower toxicity than the
usual schedule of FTM. In fact, in our series we recorded
few grade 3 toxicities, preserving patient quality of life
(QoL), which remains a crucial goal for these patients who
currently cannot be cured but only palliated. Moreover, the
patients whostarted FTMatleast3 monthsafter completion
of TMZ administration had a signiﬁcantly higher response
rate than patients who started FTM immediately after TMZ
completion. These ﬁndings are in line with similar obser-
vations reported by others [15, 33]. MGMT promoter
methylation status represents an important prognostic factor
in newly diagnosed GBM patients, and it can inﬂuence the
efﬁcacy of TMZ therapy [4]. However, after primary treat-
ment for newly diagnosed GBM, changes may occur in the
statusofMGMTpromotermethylation[34].Inourstudy,we
found a higher rate of disease control in patients with
methylated MGMT, and a trend toward prolonged PFS-6,
withoutachievingstatisticalsigniﬁcance.Thisresultreﬂects
the limited statistical power due to the relatively small
number of cases enrolled in the present trial. To the best of
our knowledge, this is the ﬁrst report speciﬁcally dealing
with use of protracted low FTM doses for induction phase.
The considerable activity and lack of toxicity of this sche-
dule open a new avenue for investigation of the possible use
of FTM in combination with targeted therapy agents.
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